INT277800

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2007
Last Reported 2008
Negated 1
Speculated 1
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 2.02
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Ms4a1)
Anatomy Link Frequency
marginal zone 2
Ms4a1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 3 57.48 Quite High
intrathecal 1 21.52 Low Low
fibrosis 4 5.00 Very Low Very Low Very Low
dexamethasone 3 5.00 Very Low Very Low Very Low
vincristine 3 5.00 Very Low Very Low Very Low
headache 3 5.00 Very Low Very Low Very Low
imagery 3 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
Inflammatory marker 2 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 137 99.98 Very High Very High Very High
Disease 51 99.52 Very High Very High Very High
B-cell Chronic Lymphocytic Leukemia 12 98.92 Very High Very High Very High
Multiple Myeloma 8 95.28 Very High Very High Very High
B-cell Lymphoma 2 86.88 High High
Follicular Lymphoma 38 81.00 Quite High
Mitral Valve Prolapse 2 65.48 Quite High
Residual Neoplasm 3 55.12 Quite High
Recurrence 13 51.44 Quite High
Mantle-cell Lymphoma 30 35.84 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The immunophenotype of marginal lymphomas is distinct from other small lymphocytic lymphomas: the antigen profile for the marginal zone lymphomas include CD19, CD20, CD22 positive and CD5, CD10, CD23, and CD11C negative.
Positive_regulation (include) of Neg (negative) Gene_expression (negative) of CD20 in marginal zone associated with b-cell chronic lymphocytic leukemia and lymphatic system cancer
1) Confidence 0.44 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721318 Disease Relevance 1.16 Pain Relevance 0
In addition, CD20 expression may change during the disease course (Robillard et al 2003; Bergua et al 2008), and it may be worthwhile occasionally repeating diagnostic evaluation.
Spec (may) Positive_regulation (change) of Gene_expression (expression) of CD20 associated with disease
2) Confidence 0.28 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 0.86 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox